You are here

Drug Forecast

A First-In-Class CGRP Receptor Antagonist as a Novel Prophylaxis Treatment for Migraine Headaches

Erenumab (Aimovig) is the first FDA-approved migraine drug that targets the calcitonin gene-related peptide (CGRP).

Martin Paspe Cruz PharmD, BCGP, BCPP, FASCP
Jayed H. Momin PharmD Candidate
Gregory J. Hughes PharmD, BCPS
Perseris: A new, long-acting, atypical antipsychotic drug-delivery system
Andrew Karas PharmD
Gary Burdge PharmD
Jose A. Rey MS, PharmD, BCPP
Shingrix, a new vaccine for herpes zoster
Fraidy Maltz BS, PharmD, BCACP
Brooke Fidler PharmD
Intranasal esketamine for treatment-resistant depression
Rebecca Bahr PharmD Candidate
Alicia Lopez PharmD
Jose A. Rey MS, PharmD, BCPP
Cannabidiol oral solution for seizures associated with Lennox-Gastaut and Dravet syndromes
Dovena Lazaridis PharmD, BCPS
Nathaniel Eraikhuemen PharmD
Kia Williams BS
Judith Lovince
Meropenem-Vaborbactam (Vabomere) for carbapenem-resistant Enterobacteriaceae
Yuman Lee PharmD, BCIDP
Juliette Kim PharmD, BCIDP
Saralinh Trinh PharmD Candidate

Influenza activity during the 2017–2018 season was high, with an estimated 48.8 million people becoming ill, 959,000 hospitalizations and 79,400 deaths. Xofulza (baloxavir marboxil) is a new antiviral agent approved by the FDA on October 24, 2018. This drug forecast article reviews the pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, safety profile, and place in therapy of Xofluza.

Kimberly E. Ng PharmD, BCPS

Steglatro (ertugliflozin) for glycemic control in adults with type-2 diabetes mellitus

Nikolas Kovacich PharmD Candidate
Benjamin Chavez PharmD, BCPP, BCACP
A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections

Alexandra Adler PharmD Candidate
Saira Chaudhry PharmD, MPH
Tamara Goldberg PharmD, BCPS